U.S., Aug. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07768124) titled 'Acupoint Application for Chemotherapy-Induced Nausea and Vomiting in Lung Cancer' on Aug. 11.
Brief Summary: This single-center, randomized, controlled study evaluates whether acupoint application added to standard 5-HT3 receptor antagonist anti-nausea medication improves control of chemotherapy-induced nausea and vomiting in adults with lung cancer receiving first-line platinum-based chemotherapy. Participants will be randomly assigned to receive either acupoint application plus a 5-HT3 receptor antagonist or the 5-HT3 receptor antagonist alone for one chemotherapy cycle. The study will compare complete control of delayed nausea an...